EWTX financial statements
The full income statement, balance sheet, and cash-flow statement for Edgewise Therapeutics Inc. (EWTX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 191M+20.5% | 159M+38.9% | 114M+59.6% | 71.7M+65.8% | 43.2M+151.4% | ||
| Research & development | 151M+19.2% | 127M+39.7% | 90.9M+68.2% | 54.0M+67.9% | 32.2M+114.8% | |
| Selling, general & administrative | 40.0M+25.6% | 31.9M+35.9% | 23.5M+33.1% | 17.6M+59.9% | 11.0M+399.1% | |
| General & administrative | 40.0M+25.6% | 31.9M+35.9% | 23.5M+33.1% | 17.6M+59.9% | 11.0M+399.1% | |
| Operating income | -191M-20.5% | -159M-38.9% | -114M-59.6% | -71.7M-65.8% | -43.2M-151.4% | |
| Pre-tax income | -168M-25.4% | -134M-33.5% | -100M | — | — | |
| Income tax | 4.00K+33.3% | 3.00K-25.0% | 4.00K | 0.00 | 0.00 | |
| Net income | -168M-25.4% | -134M-33.6% | -100M-48.1% | -67.6M-58.0% | -42.8M-150.0% | |
| -$1.63-12.4% | -$1.45+7.6% | -$1.57-24.6% | -$1.26-10.5% | -$1.14+95.1% | ||
| EPS (basic) | -$1.63-12.4% | -$1.45+7.6% | -$1.57-24.6% | -$1.26-10.5% | -$1.14+95.1% | |
| Weighted-avg shares (basic) | 103M+11.4% | 92.4M+45.0% | 63.7M+18.9% | 53.6M+42.8% | 37.5M+4978.0% | |
| Weighted-avg shares (diluted) | 103M+11.4% | 92.4M+45.0% | 63.7M+18.9% | 53.6M+42.8% | 37.5M+4978.0% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 543M+14.3% | 475M+45.4% | 327M-8.4% | 357M+25.8% | 284M+118.9% | ||
| Cash & equivalents | 61.1M+46.8% | 41.7M-51.6% | 86.1M+291.5% | 22.0M+41.3% | 15.6M-85.2% | |
| Prepaid expenses | 13.3M+149.9% | 5.31M-38.2% | 8.60M+70.3% | 5.05M+69.3% | 2.98M+441.6% | |
| 553M+13.5% | 487M+43.2% | 340M-7.4% | 367M+28.7% | 285M+117.5% | ||
| Property, plant & equipment | 7.83M-17.6% | 9.50M-9.0% | 10.4M+22.4% | 8.53M+835.6% | 912K+76.7% | |
| Operating lease right-of-use | 1.39M-11.6% | 1.57M-30.2% | 2.25M+70.5% | 1.32M | — | |
| Other non-current assets | — | 262K-24.7% | 348K+38.6% | 251K-54.2% | 548K-43.8% | |
| 27.4M+14.7% | 23.9M+42.3% | 16.8M+1.1% | 16.6M+57.6% | 10.5M+142.3% | ||
| Accounts payable | 6.01M+7.7% | 5.58M+38.6% | 4.03M-34.1% | 6.11M+58.9% | 3.84M+143.2% | |
| Accrued liabilities | 7.92M+9.6% | 7.23M+19.1% | 6.07M+4.0% | 5.84M+50.5% | 3.88M+144.5% | |
| Current lease liability | 1.01M+1.8% | 996K+1.6% | 980K+61.2% | 608K | — | |
| 30.3M+9.9% | 27.6M+30.2% | 21.2M+4.0% | 20.4M+87.9% | 10.8M+149.9% | ||
| Non-current lease liability | 2.98M-20.4% | 3.74M-15.6% | 4.43M+16.7% | 3.80M | — | |
| Other non-current liabilities | — | — | — | — | 329K | |
| 522M+13.7% | 459M+44.0% | 319M-8.0% | 347M+26.4% | 274M+921.0% | ||
| Common stock | 10.0K+11.1% | 9.00K+28.6% | 7.00K+16.7% | 6.00K+20.0% | 5.00K | |
| Additional paid-in capital | 1.07B+27.5% | 837M+48.6% | 563M+14.4% | 493M+40.0% | 352M-51.6% | |
| Retained earnings | -546M-44.3% | -379M-54.7% | -245M-69.3% | -145M-87.9% | -77.0M-125.4% | |
| Accumulated other comprehensive income | 677K+61.2% | 420K+324.2% | 99.0K+107.3% | -1.35M-163.6% | -514K | |
| Total liabilities & equity | 553M+13.5% | 487M+43.2% | 340M-7.4% | 367M+28.7% | 285M+117.5% | |
| Common shares issued | 106M+12.0% | 94.8M+34.6% | 70.5M+11.4% | 63.3M+27.8% | 49.5M+4803.6% | |
| Common shares outstanding | 106M+12.0% | 94.8M+34.6% | 70.5M+11.4% | 63.3M+27.8% | 49.5M+4803.6% | |
| Shares outstanding (cover) | 107M+12.7% | 95.2M+2.2% | 93.1M+47.2% | 63.3M+27.8% | 49.5M | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -144M-31.9% | -109M-18.6% | -91.9M-74.7% | -52.6M-57.1% | -33.5M-129.0% | ||
| Depreciation & amortization | 2.08M+0.7% | 2.07M+33.4% | 1.55M+321.5% | 368K+35.3% | 272K+47.0% | |
| Share-based compensation | 34.8M+40.6% | 24.7M+40.7% | 17.6M+60.7% | 10.9M+148.0% | 4.40M+1144.1% | |
| Change in payables | 272K-84.3% | 1.74M+1988.0% | -92.0K-295.7% | 47.0K-98.2% | 2.65M+409.4% | |
| -32.8M+82.2% | -185M-279.5% | 103M+245.8% | -70.6M+70.9% | -242M-893.5% | ||
| Capital expenditure | 256K-80.5% | 1.31M-77.2% | 5.75M+3.6% | 5.55M+730.2% | 668K+229.1% | |
| Free cash flow | -144M-30.6% | -110M-12.9% | -97.7M-67.9% | -58.2M-70.2% | -34.2M-130.3% | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 196M-21.3% | 249M+368.8% | 53.2M-59.0% | 130M-30.4% | 186M+55.0% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 187M-21.7% | 239M+354.5% | 52.6M-59.3% | 129M | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | 19.5M+143.8% | -44.4M-169.3% | 64.1M+897.4% | 6.43M+107.2% | -89.3M-210.0% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 2.66B+4.7% | 2.54B+266.1% | 694M+22.9% | 565M-25.3% | 757M | |
| P/B | 5.1×-7.9% | 5.5×+131.6% | 2.4×+52.9% | 1.6×-43.3% | 2.8× | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: EWTX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all EWTX filings on SEC EDGAR → Not investment advice.